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Abstract 
Chemoimmunotherapy is an emerging combinatorial modality for the treatment of cancers resistant to 
common first-line therapies, such as chemotherapy and checkpoint blockade immunotherapy. We used 
biodegradable nanoparticles as delivery vehicles for local, slow and sustained release of doxorubicin, two 
immune adjuvants and one chemokine for the treatment of resistant solid tumors. 
Methods: Bio-compatible poly(lactic-co-glycolic acid)-PEG nanoparticles were synthesized in an 
oil/water emulsion, using a solvent evaporation-extraction method. The nanoparticles were loaded with 
a NIR-dye for theranostic purposes, doxorubicin cytostatic agent, poly (I:C) and R848 immune adjuvants 
and CCL20 chemokine. After physicochemical and in vitro characterization the nanoparticles therapeutic 
efficacy were carried-out on established, highly aggressive and treatment resistant TC-1 lung carcinoma 
and MC-38 colon adenocarcinoma models in vivo. 
Results: The yielded nanoparticles average size was 180 nm and -14 mV surface charge. The combined 
treatment with all compounds was significantly superior than separate compounds and the compounds 
nanoparticle encapsulation was required for effective tumor control in vivo. The mechanistic studies 
confirmed strong induction of circulating cancer specific T cells upon combined treatment in blood. 
Analysis of the tumor microenvironment revealed a significant increase of infiltrating leukocytes upon 
treatment. 
Conclusion: The multi-drug loaded nanoparticles mediated delivery of chemoimmunotherapy exhibited 
excellent therapeutic efficacy gain on two treatment resistant cancer models and is a potent candidate 
strategy to improve cancer therapy of solid tumors resistant to first-line therapies. 
Key words: chemoimmunotherapy, immune modulation, immune adjuvants, multi-drug nanoparticle, 
theragnostic. 
Introduction 
Triggering antitumor immunity through 
chemotherapy, immunotherapy, or combinations 
thereof is an emerging strategy to treat solid tumors 
[1]. Besides killing cancer cells directly, some 
chemotherapies can alter the tumor 
microenvironment and enhance immune responses 
[2,3]. For example, the anthracycline doxorubicin 
(dox) has been described to induce type I interferons 
(IFNs), T cell homing through induction of the 
chemokine CXCL10, expose calreticulin on dying 
cells, and other effects [2,4]. However, dox 
monotherapy is often insufficient to clear established 
solid tumors, eliciting the need for combinatorial 
modalities. 
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Immunotherapy based on immune adjuvants 
such as cytokines, checkpoint blocking antibodies, 
Toll-like receptor (TLR) agonists and other 
compounds, are gaining attention as a strategy to 
enhance anticancer immune responses [5–9]. TLR 
agonists trigger broad inflammatory responses, elicit 
rapid innate immunity, promote the activity of 
leukocytes, and facilitate the progression from innate 
to adaptive immune responses [10]. Moreover, TLRs 
facilitate the immune system by providing context, 
allow the immune system response to skew on the 
type that is necessary and finetune the most efficient 
method to eradicate the threat to the host. Numerous 
TLR agonists have been studied as cancer therapies 
(or part of combination therapies) in clinical trials. 
Intriguingly, several agonists have demonstrated 
antitumor effects, whereas others appear to promote 
tumor growth or metastasis [11]. In humans, 
activation of the endosomal TLR3, TLR7, TLR8 and 
TLR9 typically enhances antitumor outcomes. For 
example, the TLR3 agonist Poly(I:C; pIC) has been 
reported to have potent antitumor effects on lung and 
liver cancers, and the dual TLR7/8 activator 
Resiquimod (R848) has been reported in several 
clinical trials to induce tumor regression in patients 
with advanced leukemia and skin cancers [11,12]. 
Moreover, R848 has been reported to reverse effector 
T cell senescence [13]. Interestingly, the combination 
therapy of pIC and R848 appears to be synergistic in 
vitro, but this effect has not yet been demonstrated in 
clinical trials [14]. 
To date, most clinical trials on TLR agonists 
involved the systemic administration, which led to 
deleterious adverse effects, including cytokine release 
syndrome, which can rapidly become fatal. Thus, the 
anticancer efficacy of TLR agonists is limited by 
systemic treatment. Accordingly, TLR agonists are 
being actively explored within combination therapies 
administered intratumorally. Chemokines are specific 
immune adjuvants that can induce chemotaxis of 
immune cells to the tumor, thereby making tumors 
more visible to immune cells. Similarly to TLR 
agonists, some chemokines may exert anticancer 
effects, whereas others may enhance cancer 
progression depending on the cancer type, the tumor 
microenvironment phenotype, and the cancer stage 
[15]. One chemokine that can drive immune cells 
towards the tumor is the Macrophage Inflammatory 
Protein-3 alpha (MIP3α; CCL20) which attracts cells 
expressing CCR6/CD196 such as (memory) T cells, 
natural killer cells and immature dendritic cells (DCs), 
all of which can mediate tumor regressions [16–19]. 
Furthermore, MIP3α has also been described to 
directly repress the proliferation of myeloid 
progenitors [20]. 
Successful therapeutic responses are commonly 
observed when the effective dose of a drug is 
maintained at the target site for a specific duration. 
However, drugs that are administered systemically 
can generate numerous off-target effects that 
compromises the therapy efficacy. In response, either 
the dose is adjusted or the treatment is stopped, both 
of which can be problematic for the survival of the 
patient. Therefore, for certain anticancer drugs, local 
administration may prove more effective than 
systemic administration [5]. However, one 
disadvantage of local treatment is rapid diffusion, 
which limits efficacy. Therefore, an attractive route of 
administration would be one that is local, to avoid 
off-target effects, but in which the drug is released 
slowly for a sustained period, to maximize efficacy. 
This approach entails the use of drug delivery 
vehicles such as liposomes, metallic nanoparticles 
(NPs) or biodegradable poly(lactic-co-glycolic acid; 
PLGA) polymers [21,22]. Indeed, delivery of cancer 
therapeutics with such vehicles is rapidly gaining 
recognition for its advantages. For instance, over the 
past several years, the FDA approved nano-vehicle 
formulations of previously developed 
chemotherapeutics: Doxil®, Abraxane®, and 
Onivyde® for dox, paclitaxel, and irinotecan, 
respectively. Interest in drug delivery vehicles is also 
reflected by the large number (>200) of clinical trials 
currently underway in which chemotherapeutics are 
being compared to their respective soluble and 
delivered forms [23–25]. 
Herein, we report the assembly and in vitro 
functional characterization and loading of PLGA NPs 
with dox, pIC, R848 and MIP3α, and subsequent in 
vivo evaluation of the loaded NPs as a cancer therapy. 
We assessed the activity of our drug-loaded NPs in 
two aggressive and treatment resistant murine 
models of cancer: TC-1 lung carcinoma and MC-38 
colon adenocarcinoma. We provide evidence of 
enhanced potential of chemotherapy and 
immunotherapy. Finally, we investigated the in vivo 
efficacy of the NP delivered drugs against the 
corresponding free drugs and analyzed the tumor 
microenvironment. To the best of our knowledge, this 
is the first published study to combine NP mediated 
delivery of a chemotherapeutic agent, two distinct 
TLR agonists and a chemokine into a single 
theranostic modality. 
Materials and methods 
Materials and reagents 
PLGA polymer (lactide/glycolide molar ratio of 
48:52 to 52:48) was purchased from Boehringer 
Ingelheim (Ingelheim am Rhein, Germany). Solvents 
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for synthesizing the PLGA NPs including 
dichloromethane (DCM; CAS 75-09-2 CH2CL2 MW 
84.93) and polyvinyl alcohol (PVA; CAS 9002-89-5) 
were purchased from Sigma-Aldrich (Zwijndrecht, 
The Netherlands). Chloroform (CHCL3 MW 119.38 
g/mol) was purchased from Merck (Darmstadt, 
Germany). Lipid-PEG 2000 (1,2-Distearoyl- 
sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Pol
yethylene glycol)-2000]; powder MW 2805.54) was 
purchased from Avanti Polar Lipids (AL, USA). The 
near infrared (NIR) dye (IR-780 Iodide; CAS 
207399-07-3) was purchased from Sigma-Aldrich; 
R848 from Alexis Biochemicals (Paris, France); 
poly(inosinic:cytidylic acid; CAS 42424-50-0 P0913) 
from Sigma-Aldrich; MIP3α from R&D Systems (MN, 
USA) and doxorubicin HCL powder from Actavis 
(Munich, Germany). 
Synthesis of PLGA NPs 
The NPs were synthesized in an oil/water 
emulsion, using a solvent evaporation-extraction 
method. Briefly, 200 mg of PLGA was dissolved in 6 
mL of DCM containing 1 mg of NIR dye. Depending 
on the NP, the following was added: 40 mg of dox, 8 
mg of pIC and/or 4 mg of R848 and/or 250 µg of 
MIP3α. Next, the solution containing the NP 
constituents was added dropwise to 40 mL of aqueous 
2.5% (w/v) PVA and emulsified for 120 s using a 
sonicator (250 watt; Sonifier 250; Branson, Danbury, 
USA). Next, the previously described solution was 
transferred to a new vial that contained an air-dried 
solution of 40 mg of Lipid-PEG 2000 dissolved in 0.4 
mL of chloroform and homogenized for 60 s by 
sonication. Following overnight evaporation of the 
solvent at 4 °C, the NPs were collected by 
ultracentrifugation (12,800 rpm for 30 minutes) at 4 
°C, washed four times with distillated water, and 
lyophilized for 3 days. The concentration of each 
encapsulated constituent (dox, pIC, R848 and MIP3α) 
was determined by distinct methods, as described 
elsewhere [26]. In brief, the concentration of the TLR 
agonists (pIC and R848) were determined by reverse 
phase high-performance liquid chromatography 
(RP-HPLC) at room temperature using a Shimadzu 
system (Shimadzu Corporation, Kyoto, Japan) 
equipped with a RP-C18 symmetry column (250 mm x 
4.6 mm). The flow rate was fixed at 1 mL/min and 
detection was obtained by UV detection at 254 nm. A 
linear gradient of 0% to 100% of acetonitrile (0.036% 
TFA) in water containing 0.045% TFA was used for 
the separation of pIC and R848. The peak of R848 was 
well separated from that of the pIC in the established 
chromatographic condition. The retention times of the 
pIC and R848 were approximately 19 and 26 min, 
respectively. The regression analysis was constructed 
by plotting the peak-area ratio of R848 or pIC versus 
concentration (µg/mL). The calibration curves were 
linear within the range of 1 µg/mL to 10 µg/mL for 
R848 and 1 µg/mL to 150 µg/mL for pIC. The 
correlation coefficient (R2) was always greater than 
0.99, indicating a good linearity. The concentration of 
pIC and R848 was calculated by interpolation into the 
standard curves as described previously. The 
concentration of MIP3α was determined by 
RP8-HPLC at room temperature using a Shimadzu 
system (Shimadzu Corporation) equipped with a 
RP-C8 symmetry column (150 mm x 4.6 mm). The 
flow rate was fixed at 0.8 mL/min and detection was 
obtained by UV detection at 220 nm. A linear gradient 
of 5% to 80% of acetonitrile (0.036% TFA) in water 
containing 0.045% TFA was used. The concentration 
of the NIR dye was measured at 800 nm relative to a 
standard curve using an Odyssey scanning (Li-Cor) as 
per described previously [27]. The dox concentration 
was determined by SpectraMax® iD3 multi-mode 
microplate readers via fluorescence with an excitation 
peak at 488 nm and emission peak at 530 nm. The 
loading capacity was calculated as follows: 
Percentage loading capacity = [entrapped drug /NP 
yield weight] * 100 
Physicochemical properties of the NPs 
The NPs were characterized for average size, 
polydispersity index and surface charge 
(zeta-potential) by dynamic light scattering. Briefly, 50 
µg of NP sample in 1 mL of ultrapure MilliQ H2O 
were measured for size using a Zetasizer (Nano ZS, 
Malvern Ltd., UK) and a similar sample was analyzed 
for surface charge by laser Doppler electrophoresis on 
the same device. 
Particles surface and morphology 
To visualize the structure of the NPs, 
transmission electron microscopy (TEM) was used. 
Briefly, a formvar support film attached to a copper 
grid (100 mesh) was coated with carbon and 
hydrophilized by glow-discharging for 30 s with a 
current of 25 mA. A droplet of 3 µL of the NPs 
solution was applied to the grid and then stained for 1 
min in distilled water containing 2.3% uranyl acetate. 
Next, the grid was air-dried and imaged in a Tecnai 12 
Biotwin transmission electron microscope (FEI, The 
Netherlands), equipped with a LaB6 filament 
operated at 120 keV. The sample was imaged 3 µm 
under focus with binning 2 on a 4kx4k Eagle CCD 
camera with a magnification of 18,500x. 
Atomic force microscopy (AFM) was employed 
to study the surface morphology and size of NPs. 
Briefly, a drop of diluted and dispersed NPs 
suspension was placed on a clean glass surface glued 
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to the AFM stub. The dried NPs were then visualized 
with AFM (JPK Nano Wizard 3) in AC mode (tapping 
mode), using OMCL-AC160TS silicon probes 
(Olympus), with nominal resonance frequency of 300 
kHz and nominal spring constant of 26N/m. The 
images were analyzed using Gwyddion SPM 
Software (Czech Metrology Institute, Czech 
Republic). The 2D visualization was performed with 
JPK Data Processing Software (JPK Instruments, 
Germany) and the images were converted to 3D using 
Gwyddion v. 2.52 (open source SPM data analysis 
software). 
Stability study and release kinetics of the NPs 
For the NP stability study a total of 10 mg of each 
described NP was carefully dissolved in 2 mL of PBS 
and kept at room temperature and at constant rotating 
velocity. At the designated time points a 50 µL sample 
was taken from the supernatant and measured by 
dynamic light scattering as per described above. For 
the NP release kinetics study, 1 mL (10 mg/mL) of the 
NP containing all drugs was pipetted into a dialysis 
bag (MWCO 1000), which was immersed into a tube 
containing 30 mL of PBS (pH 7.4). The tubes were 
placed on a shaking bed at 100 rpm and 37 °C. At the 
described time points, 30 mL of the release medium 
was collected and replenished with 30 mL of fresh 
PBS. The collected sample was concentrated by 
lyophilization in order to determine the content 
released for all components. The dox, NIR dye, TLR 
agonists R848 and pIC concentration were determined 
as per described above. 
Cell lines 
The murine tumor cell line TC-1 (a kind gift from 
T.C. Wu, Johns Hopkins University, Baltimore, MD, 
USA) was generated by retroviral transduction of 
lung fibroblasts of C57BL/6 origin, to express the 
HPV16 E6 and E7 genes and the activated human 
c-Ha-ras oncogene [28]. The C57BL/6 MC-38 colon 
adenocarcinoma cell line was kindly provided by 
Mario Colombo. The D1 cell line is an immature 
splenic DC line derived from B6 mice which harbors 
most of the typical characteristics of that of bone 
marrow derived DCs [29]. The TC-1 cell line was 
cultured in DMEM medium (BioWhittaker, Verviers, 
Belgium) supplemented with 8% heat-inactivated 
fetal calf serum (FCS; Greiner bio-one, Alphen a/d 
Rijn, The Netherlands), penicillin (50 μg/mL; Gibco, 
Paisley, Scotland), streptomycin (50 μg/mL; Gibco), 
L-glutamine (2 mM; Gibco) and β-mercaptoethanol 
(20 μM; Sigma, Saint Louis, USA). In addition, the 
TC-1 cells were co-cultured with the corresponding 
selective agent Geneticin (G418; 400 μg/mL). The 
BALB/macrophage cell line RAW264.7 and the 
MC-38 cell line were cultured identically to the TC-1 
cell line except that IMDM medium was used and no 
selection agent was applied. The D1 cell line was 
cultured as described previously [30]. All the above 
described cell lines were incubated at 37º C in 5% CO2 
and 100% humidity. Furthermore, the cell lines were 
confirmed to be free of mycoplasma and were 
regularly tested for eighteen common rodent viruses 
by PCR analysis. 
Mice strains 
C57BL/6 (H-2b haplotype) mice were purchased 
from Envigo (Horst, The Netherlands). They were all 
female and ranged in age from 8 to 12 weeks. The 
mice were housed at the animal facility of Leiden 
University Medical Center under specific pathogen 
free conditions. All animal experiments were 
approved by the Dutch Central Committee on Animal 
Experimentation and were strictly conducted 
according to the Dutch animal welfare law. 
Intracellular uptake of NPs and 
immunostaining 
Intracellular uptake of NPs was determined by 
incubating either 10 µg/mL or 20 µg/mL of NPs 
containing NIR dye (~ 800 nm; described above) with 
1x104 TC-1 or D1 cells for 1 hour, 2 hours or 4 hours. 
To remove unbound NPs from the cells and wells, the 
cells were harvested and moved to a new 96-well 
plate and washed several times. Then, the cells were 
placed in a black 96-well microplate (Greiner bio-one, 
Germany), fixed with 1% paraformaldehyde (PFA) 
and stained with To-pro 3 iodide (642/661 ~700 nm; 
Invitrogen; Eugene, USA) to enable cell count. Finally, 
the NIR dye signal in each cell line was scanned using 
an Odyssey scanner infrared imaging system 
(LI-COR). Immunostaining detected by fluorescence 
microscopy was determined by incubating 20 µg/mL 
of NPs containing NIR dye with TC-1 or D1 cells in 
the chambers of a glass culture slide (FALCON, NY, 
USA) for 48 hours. After washing, and fixating the 
cells with 4% PFA, the cells were stained with 
anti-CD44-PE (clone GL1, eBioscience) for membrane 
visualization, washed again with PBS and finally, 
mounted with VectaShield antifade mounting 
medium with DAPI to stain nuclei (Vector 
Laboratories, CA, USA). Digital images were acquired 
using a Leica DM6B microscope. 
Activation and maturation of DCs 
DC activation and maturation were assessed 
based on upregulation of CD86 on the D1 cells and 
production of IL-12 in the supernatant. Briefly, a 
solution of pIC and an equivalent concentration of 
pIC encapsulated in NPs, that also contained R848 
and MIP3α, were separately prepared according to 
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annotated concentrations (see corresponding figure 
legends). The solutions were then distributed into 
96-well plates and sequentially diluted, after which 
5x104 D1 cells were added to each well and allowed to 
incubate for 48 hours at 37º C in 5% CO2 and 100% 
humidity. The supernatant was then harvested and 
analyzed with an ELISA (described below). The cells 
were used to analyze the CD86 expression with 
anti-CD86-APC (clone GL1, eBioscience) on an LSR-II 
laser flow cytometer controlled by CELLQuest 
software v. 3.0 (Becton Dickinson, Franklin Lakes, 
USA) and analyzed with FlowJo LLC v. 10 software 
(Tree Star, USA). The interleukin IL-12 was detected 
using a standard sandwich ELISA with bottom 
polystyrene ELISA plates (Corning, Kennebunk, 
USA). Purified anti-mouse IL-12/IL-23 p40 (clone 
C15.6, Biolegend) and biotin-labelled anti-mouse 
IL-12/IL-23 p40 antibodies (clone C17.8, Biolegend) 
were used. Streptavidin-horse radish peroxidase (1 
μg/mL; Biolegend) and 3,3′,5,5′-tetramethyl benzidine 
(TMB; Sigma-Aldrich) was used to generate the 
detection signal. Finally, the plates were read at 450 
nm using a Bio-rad 680 microplate reader (Bio-rad 
Laboratories). 
Cytotoxicity of empty and dox-loaded NPs 
The toxicity of empty NPs to DCs was 
determined by incubating DCs (5x104) with increasing 
concentrations of empty NPs for 48 hours, and then 
measuring cell viability. The cytotoxic compound 
dimethyl sulfoxide (DMSO; CAS 67-68-5; Honeywell, 
MI, USA) 25% (v/v) in medium was included as a 
positive control (100 percent cell death). To measure 
viability, the cells were stained with 7-AAD 
(Invitrogen) using standard protocols and then 
subjected to flow cytometry measurements on an 
LSR-II laser flow cytometer controlled by CELLQuest 
software v. 3.0 (Becton Dickinson). The cell toxicity of 
the dox-loaded NPs and controls was determined by 
using the CellTiter 96 AQueous one solution cell 
proliferation assay (MTS; Promega, Madison, USA) 
performed per manufacturer’s instructions. In brief, 
5x103 cells per well were distributed into a 96-wells 
plate and treated with indicated concentrations of 
compounds at 37º C in 5% CO2 and 100% humidity. 
After 72 hours, cells were incubated with MTS 
solution before measuring absorbance at 490 nm 
using a Bio-rad 680 microplate reader (Bio-rad 
Laboratories). 
Transwell chemotaxis assay 
A solution of NP(pIC+R848+MIP3α) in full 
medium was prepared at an equivalent MIP3α 
concentration of 1 µg/mL. Separately, a solution of 
free MIP3α at a matching concentration of 1 µg/mL, 
and a positive control solution of free MIP3α at 10 
µg/mL, were prepared and distributed into the wells 
of a Transwell permeable 24-well plate (12x6.5 mm 
inserts; 8.0 µm PET membrane (Costar Corning, 
Kennebunk, USA). After 24 hours of incubation at 37 
ºC, to allow sufficient MIP3α to be released from the 
NPs, the insert was pre-warmed with warm complete 
culture medium and the lower chamber solution was 
carefully re-suspended to homogenize MIP3α into the 
solution. Next, 1x105 RAW264.7 cells were carefully 
added to each upper chamber insert and allowed to 
migrate for 24 hours. Next, the cells were fixed with 
4% PFA, washed and stained with a crystal violet 
solution, after which several digital pictures of each 
insert were acquired with a reverse microscope. Cell 
migration was quantified using Image J software v. 
1.5. The migration index was calculated by dividing 
the area (%) of migrated cells by the area (%) of 
migrated cells induced by the positive control. 
Tumor challenge with NP-delivered 
combination therapy 
Mice were inoculated with 1x105 TC-1 or 4x105 
MC-38 cells in 0.2 mL PBS in the right flank. When the 
tumors became established at day 8 after tumor 
inoculation, each mouse received a 30 μL intratumoral 
injection of NPs dissolved in PBS and this was 
repeated every other day (four injections in total), 
unless otherwise specified. The control (untreated) 
group received an intratumoral injection of 30 μL PBS 
every other day (four injections in total), unless 
otherwise specified. Each intratumoral treatment 
administration contained, in total: 1.5 mg/Kg (30 µg) 
of dox, 1.2 mg/Kg (24 µg) of pIC, 375 μg/Kg (7.5 µg) 
of R848, and 75 µg/Kg (1.5 µg) of MIP3α in NP stock 
concentration of ca. 50 mg/mL. Concentrations were 
matched for the groups treated with free therapies. 
The limiting concentration of NPs for the experiments 
(see figure legends) was the MTD of dox: 6 mg/Kg (4x 
1.5 mg/Kg) [31]. For the reduced dose experiment, the 
cumulative dose was 3 mg/Kg. For the dox and 
immune adjuvants combined experiments, pIC, R848 
and MIP3α content was matched among groups on 
dox or on pIC, R848 or MIP3α content. Tumor 
dimensions were measured every other day with a 
standard caliper and the volume was calculated by 
multiplying the tumor diameters in all three 
dimensions. The maximal allowed tumor volume was 
2,000 mm3; after this point, mice were sacrificed, 
which formed the basis for the Kaplan-Meier survival 
curves. 
Blood analysis 
The presence of antigen-specific T cells in the 
blood of each mouse was determined by collecting 50 
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µL of blood via a puncture of the caudal vein at day 8 
and day 16 after the first treatment. After removal of 
red blood cells by lysis, the cells were stained with 
anti-CD8α-PE (clone 53-6.7, eBioscience) and 
anti-CD3-eFluor 450 (clone 17A2, eBioscience). For 
mice bearing TC-1 tumors, the APC labeled HPV16 
E749-57 (RAHYNIVTF) MHC class I (H-2Db) tetramer 
was added to the staining mix. After thorough 
washing, the cells were subjected to flow cytometry 
measurements on an LSR-II laser flow cytometer 
controlled by CELLQuest software v. 3.0 (Becton 
Dickinson) and the data analyzed with FlowJo LLC v. 
10 software (Tree Star). 
Tumor microenvironment and spleen analysis 
The tumor microenvironment and the spleens of 
mice were analyzed ex vivo by sacrificing the mice 
and resecting the tumors and the spleens at day 18 
after tumor inoculation (after a single treatment at day 
8). From the six mice per group, only four mice were 
selected for analysis based on their similar tumor size. 
The resected tumors were then mechanically broken 
up into small pieces of ~2-3 mm in diameter (with 
sterile tweezers and scissors) and incubated with 
Liberase TL (Roche, Mannheim, Germany) in 
serum-free IMDM medium for 15 minutes at 37 ºC. 
Single cell suspensions of the tumors and the spleens 
were acquired by gently grinding the tumor 
fragments and the spleens through a 70 µm cell 
strainer (Falcon, NY, USA) each in separate 50 mL 
tubes. The red blood cells from the spleens where 
removed by lysis. Each tube containing the single cells 
were then equally divided to be stained with two 
distinct antibody panels. One panel contained the 
viability dye 7-AAD (Invitrogen) and the following 
antibodies against cell surface markers: 
anti-CD45.2-APC eFluor 780 (clone 104, eBioscience); 
anti-CD3-eFluor 450 (clone 17A2, eBioscience); 
anti-CD4-Brilliant Violet 605 (clone RM4-5, 
Biologend), and anti-CD8α-APC-R700 (clone 53-6.7, 
BD Bioscience). The other panel contained the 
viability dye 7-AAD (Invitrogen) and the following 
antibodies against cell surface markers: 
anti-CD45.2-FITC (clone 104, BD Bioscience); 
anti-CD11b-eFluor 450 (clone M1/70, eBioscience); 
anti-F4/80-PE (clone BM8, eBioscience); 
anti-Ly6G-AlexaFluor 700 (clone 1A8, Biolegend); 
anti-Ly6C-Brillian Violet 605 (clone HK1.4, 
Biolegend), and anti-CD11c-APC-eFluor 780 (clone 
N418, eBioscience). After thorough washing, the cells 
were subjected to flow cytometry measurements on 
an LSR-II laser flow cytometer controlled by 
CELLQuest software v. 3.0 (Becton Dickinson) and the 
data analyzed with FlowJo LLC v. 10 software (Tree 
Star). The gating strategy is depicted in Figure S1. 
Data and statistical analysis 
Statistical analysis was performed using 
GraphPad Prism v. 7.0 software (GraphPad Software, 
La Jolla, USA). Data are represented as mean values ± 
SD unless stated otherwise. Tumor volumes, blood 
tetramer and tumor and spleen cell analysis results 
were compared on a fixed day between mouse groups 
and statistical significance was determined by using 
an unpaired, non-parametric, two-tailed 
Mann-Whitney U test. Survival curves were 
compared using the Gehan-Breslow-Wilcoxon test 
unless stated otherwise. Statistical differences were 
considered significant at p < 0.05 and presented as: * p 
< 0.05, ** p < 0.01, *** p < 0.001. 
Results 
Physicochemical properties and in vitro 
characterization of the NPs 
We loaded NPs with dox and/or different 
immune adjuvants and then studied their therapeutic 
potential (Table 1). The tumor immunity of the 
monotherapy NPs containing only immune adjuvants 
were studied separately (manuscript submitted). Due 
to the limited in vivo detection capability of the 
fluorescent anthracycline doxorubicin, we loaded a 
NIR dye in each batch of NPs to enable in vivo 
theranostic analysis and the NPs were functionalized 
with surface PEGylation (PEG). The NPs were first 
characterized to ascertain their size and surface 
charge (Table 1 and Figure S2). The average size was 
approximately 180 nm and differed depending on the 
cargo. The average ζ potential was slightly negative: 
ca. -14 mV. The NPs were stable in PBS for at least 8 
weeks (Figure S3). TEM and AFM analysis revealed 
that the NPs were all spherical with a smooth surface 
and uniform sizes (Figure 1). 
Drug release kinetics 
We measured the drug release kinetics of the 
NPs dissolved in PBS and kept at 37°C in a 
thermo-shaker at a constant shaking velocity. The NPs 
exhibited a sustained release profile with different 
release kinetics for each drug (Figure 2A). After 12 
days, approximately 50% of pIC was released, 35% of 
dox, 25% of R848 and the NIR dye, respectively. 
MIP3α release could not be determined because it was 
below the detection limit. The profile release of pIC 
was the most rapid compared to the other drugs due 
to its high hydrophilicity property. The other 
encapsulated compounds show a typical drug profile 
release from the PLGA (lactide/glycolide molar ratio 
of 50:50) standard polymer. These results suggest that 
the NPs release drugs in a slow, sustained manner. 
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Table 1. Physicochemical characterization of the NPs 
    Loading capacity (% w/w) 
Samples Diameter ζ Potential (mV) PDI NIR Dox pIC R848 MIP3α 
NP(NIR)-PEG 
Denoted as NP(empty) 
187.4 ± 44.7 -13.9 ± 6.2 0.064 63.6 ± 1.4 - - - - 
NP(NIR+dox)-PEG 
Denoted as NP(dox) 
185.9 ± 28.2 -13.5 ± 7.5 0.127 64.9 ± 0.9 13,9 ± 1.8 - - - 
NP(NIR+pIC+R848+MIP3α)-PEG 
Denoted as NP(pIC+R848+MIP3α) 
177.3 ± 86.6 -14.3 ± 4.9 0.120 61.1 ± 7.8 - 47.7 ± 2.6 58.4 ± 3.2 63.8 ± 5.0 
NP(NIR+dox+pIC+R848+MIP3α)-PEG 
Denoted as NP(dox+pIC+R848+MIP3α) 
177.3 ± 86.8 -14.3 ± 4.9 0.120 62.8 ± 5.6 6.3 ± 1.1 37.9 ± 10.1 17.1 ± 3.8 63.9 ± 3.8 
Physicochemical characterization of the PLGA-PEG NPs containing dox and/or different immune adjuvants. The PLGA NPs were characterized by dynamic light scattering 
and zeta potential measurements. PLGA NPs size and zeta potential data represent the mean value ± SD of 10 readings of one representative batch. The loading capacity of 
dox and NIR dye was measured by fluorescence method. The loading capacity of pIC, R848 and MIP3α was determined by RP-HPLC analysis. The loading capacity data 
represent the average value ± SD of batch variation. 
 
 
Figure 1. NPs surface and morphology. (A) Representative morphology image of NP(empty) obtained by TEM. (B) AFM 2D image. (C) AFM 3D image. 
 
Cellular uptake of the NPs 
Since dox, pIC and R848 all exert their biological 
effects intracellularly (unlike MIP3α), we sought to 
assess the uptake of drug-loaded NPs by cells. To this 
end, NPs containing NIR dye (at 10 µg/mL and at 20 
µg/mL) were incubated with TC-1 cells for 1 hour, 2 
hours and 4 hours (Figure 2B). At 10 µg/mL, the 
signal was detected after 2 hours and 4 hours of 
incubation, but not after 1 hour. At 20 µg/mL, the 
signal was detected at all three time points, and it 
increased with increasing incubation time. To 
determine whether the signal was originating from 
inside the cells, the NPs were incubated with TC-1 
cancer cells again for 2 hours at 20 µg/mL and 
observed under fluorescence microscopy (Figure 2C). 
The NIR signal (green) from the NPs was observed 
within cells, indicating that the NPs had released their 
content into the cells. Similar results were observed 
when these experiments were performed with DCs 
instead of TC-1 cells (data not shown). 
NPs enhance DC activation, IL-12 production, 
and induce chemotaxis 
The ligands pIC and R848 are agonists for the 
endosomal TLR3 and TLR7/8, respectively, which are 
predominantly located inside cells. Activation of 
TLR3 or TLR7/8 can be detected by measuring the 
expression of CD86 in D1 DCs. For this purpose, 
NP(pIC+R848+MIP3α) was incubated at increasing 
concentrations with DCs for 48 hours. The loaded NPs 
caused a dose-dependent increase in CD86 
expression, whereas empty NPs at equivalent 
concentrations did not (Figure 2D). Moreover, 
incubation with NP(pIC+R848+MIP3α) triggered 
IL-12 secretion by DCs, indicating that these cells had 
been activated and that the TLR agonists in the NPs 
had remained active (Figure 2E). To determine the 
activity of MIP3α after co-encapsulation in NPs, the 
chemotactic capacity of this chemokine was assessed 
by incubating NP(pIC+R848+MIP3α) with medium in 
the lower chamber of a transwell system (Figure 2F). 
MIP3α was observed to attract approximately three 
times the number of cells across the membrane 
compared to medium only, indicating that, like the 
TLR agonists, MIP3α also had remained active after 
co-encapsulation in the NPs. 
Cytotoxicity of empty and loaded NPs 
We next sought to determine the cytotoxicity of 
the empty and loaded NPs (dox only, immune 
adjuvants only or combinations thereof). First, DCs 
were co-cultured in vitro with empty NPs for 48 hours 
at increasing NP concentrations, subsequently stained 
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with the cell death marker 7-AAD, and finally, 
analyzed by flow cytometry (Figure 2G). The empty 
NPs did not induce any significant cytotoxicity, as 
measured by the low signal of 7-AAD relative to the 
signal of the DMSO control. Next, to ascertain the 
effects of loading dox into NPs on its 
chemotherapeutic activity, an MTS cytotoxicity assay 
was performed by treating TC-1, MC-38 cells and DCs 
with dox-loaded NPs (Figures 2H, 2I and S4A, 
respectively). In all cell lines, cytotoxicity was 
dose-dependent. For TC-1 and MC-38 the dox-loaded 
NPs provoked ten times the level of cell death as did 
the free dox. The LD50 of dox in MC-38 cells (ca. 200 
ng/mL) was half of that of TC-1 cells (ca. 400 ng/mL). 
However, the NPs with immune adjuvants alone did 
not induce cell death in either cell line. In addition, we 
compared the effect of multi-drug encapsulation of 
NP(dox+pIC+R848+MIP3α) and of NP(pIC+R848+ 
MIP3α) versus non-encapsulated (soluble) controls on 
cell viability (Figure S4). NP(pIC+R848+MIP3α) or the 
soluble controls did not affect cell viability. On the 
other hand, NP(dox+pIC+R848+MIP3α) was more 
efficient in killing cells than the soluble controls. 
Overall, these results indicate that empty NPs are 
non-cytotoxic to DCs and that NP-delivered dox 
shows greater cytotoxicity to two cancer cell lines than 
does free dox. 
Intratumoral co-delivery of dox with immune 
adjuvants boosts lymphocyte influx in the 
tumor microenvironment 
To assess alterations in the tumor and spleen 
upon treatment, we analyzed the lymphoid and 
myeloid populations of mice bearing TC-1 tumors. 
Mice were either treated with a single intratumoral 
injection of NP(dox+pIC+R848+MIP3α) or a mock 
injection with PBS at day 8. The tumors and spleens 
were resected 10 days afterwards and analyzed ex 
vivo. Compared to the mock treated mice, the treated 
mice exhibited significantly higher levels of 
leukocytes in the tumor, as measured by cell staining 
for the pan-leukocyte marker CD45 (Figure 3A). 
Moreover, the treated mice showed significantly 
higher levels of CD3+ and CD4+ T cells in the tumor 
(Figures 3B & 3C). However, although they also 
showed higher levels of CD8+ T cells, this difference 
was not statistically significant (Figure 3D). In the 
spleen, the number of leukocytes was not found to 
differ significantly between the control and treated 
groups (data not shown). Moreover, no significant 
differences in the tumoral or splenic myeloid 
populations were observed between the two groups 
(Figures 3E & 3F). These results indicate that 
intratumoral treatment of TC-1 tumors with 
NP(dox+pIC+R848+MIP3α) enhances the lymphoid 
cell populations in the tumor but not in the spleen, 
and does not alter the myeloid population within the 
tumor microenvironment. 
Intratumoral co-delivery of dox and immune 
adjuvants by NPs augments the levels of 
circulating CD3+, CD8+ and cancer 
antigen-specific CD8+ T cells 
To determine whether the combined 
chemoimmunotherapy approach can alter the levels 
of circulating lymphocytes, we collected blood at day 
16 and at day 26 (8 and 16 days post-treatment) from 
mice with TC-1 tumors and measured the number of 
CD3+, CD8+ and cancer antigen-specific CD8+ T cells. 
We observed that on day 16, the percentage of CD3+ 
and CD8+ T cells was not found to be significantly 
different (Figure 4A & 4B, respectively). However, 
treatment of mice with NP(dox+pIC+R848+MIP3α) 
induced a significant increase in cancer 
antigen-specific CD8+ T cells, compared to 
intratumoral administration of free dox or PBS alone 
(Figure 4C). At day 26, the average number of CD3+ 
and CD8+ T cells was higher in the blood of mice 
treated with NP(dox+pIC+R848+MIP3α) than mice 
treated with dox only, but this difference was not 
statistically significant (Figures 4D & 4E). In contrast 
to day 16, at day 26 there were no differences in the 
levels of cancer-specific CD8+ T cells among the three 
groups (Figure 4F). 
Intratumoral co-delivery of dox and immune 
adjuvants by NPs provides enhanced 
chemoimmunotherapeutic effects in mice with 
established tumors 
Next, we determined the respective therapeutic 
contributions of dox and of the immune adjuvants 
(pIC, R848 and MIP3α). Treatment was initiated with 
one intratumoral injection at 8 days post-inoculation, 
followed by three additional consecutive 
administrations at days 10, 12 and 14 (Figure 5A). The 
NPs were detectable with IVIS fluorescence imaging 
for at least 168 hours in the tumor after last injection 
(Figure S5). A significant therapeutic effect was 
observed for all the tumors treated with NPs 
containing dox alone, the immune adjuvants alone or 
the combination therapy but not for the empty NPs 
(Figures 5B & 5C). The greatest statistically significant 
therapeutic effect was provided by the combination 
therapy, followed by the monotherapies; however, 
there was no significant therapeutic difference 
between either monotherapy. These results 
corroborate an enhanced effect between dox and the 
immune adjuvants when intratumorally co-delivered 
by NPs. 
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Figure 2. In vitro cumulative release kinetics, cellular uptake, DC activation, and cytotoxicity of the empty and drug-loaded NPs. (A) NP release kinetics of 
encapsulated drugs simulated at 37°C in PBS and kept in a thermo-shaker at a constant shaking velocity. n = 3 from one representative experiment. (B) Uptake of NPs containing 
NIR dye (800 nm) by TC-1 cells (To-pro 3 iodide; 700 nm) over the times indicated. n = 3 from one representative experiment. (C) Uptake of NPs by TC-1 cells after 2 hours 
of incubation, shown by fluorescence microscopy. Red: cell membrane; purple: cell nucleus; green: NIR dye. (D) Activation of DCs measured by CD86 expression upon 48 hours 
incubation with NP(pIC+R848+MIP3α). NP(empty) and isotype controls are shown in red and grey, respectively. The cells were pooled from n = 3 from each condition, one 
representative out of three independent experiments. (E) Activation of DCs measured by the secretion of IL-12p40 upon 48 hours incubation with NP(pIC+R848+MIP3α). 
NP(empty) and pIC controls are shown in red and black, respectively. n = 3 from one representative out of three independent experiments. (F) Migration assessment using 
Boyden chamber assay. After 24 hours of pre-incubation of the lower chamber with either MIP3α (in solution) or NP(pIC+R848+MIP3α), RAW264.7 cells were added to the 
upper chamber and allowed to migrate for 24 hours. Medium was used as a negative control. n = 3 from one representative out of two independent experiments. (G) 
Cytotoxicity measurement of empty NPs on DCs incubated with increasing concentrations for 48 hours. The cytotoxic compound DMSO (black bar) was used as a positive 
control (100 percent of cell death). (H+I) Cell viability assessed by MTS cell proliferation assay upon 72 hours incubation with indicated compounds on TC-1 (H) or MC-38 (I) 
cells. n = 3 from one representative out of four independent experiments. All data are presented as mean ± SD. 
 
Intratumoral co-delivery of dox and immune 
adjuvants by NPs induces strong tumor 
regression and better overall survival than 
does of free components 
To further assess the therapeutic advantage of 
our NPs, we compared intratumoral treatment of free 
dox, the free combination therapy 
(dox+pIC+R848+MIP3α) and the NP-delivered 
combination therapy in two murine models of cancer: 
MC-38 and TC-1, using immunocompetent C57BL/6 
mice. Treatment was initiated at day 8, followed by 
three additional consecutive administrations at days 
10, 12 and 14 (Figure 6A). The concentrations of the 
free compounds were matched to the concentrations 
of the compounds loaded inside the NPs. The tumors 
in mice treated with free dox monotherapy did not 
regress in either model (Figure 6B). Unlike the TC-1 
tumors, the MC-38 tumors did initially respond to the 
free combination therapy. The greatest gain in overall 
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survival in both models was observed for the 
NP-delivered combination therapy (Figure 6C & 6D). 
Importantly, halving the total dose of NP-delivered 
combination therapy and increasing the time between 
administrations gave sustained, measurable 
responses in both models, but failed to completely 
cure any mouse (Figures S6A to S6D). In both models, 
the effects of all treatments on weight gain was 
minimal (Figure 6E & 6F). However, at day 25, the 
weight of MC-38 mice treated with either combination 
therapy (NP or free) was slightly lower than that of 
the mice treated with dox alone. Furthermore, all the 
mice whose tumors had been eradicated later rejected 
a tumor re-challenge, which indicates development of 
functional immunological memory against tumor 
antigens (data not shown). In conclusion, these results 
indicate that the NP-delivered combination therapy of 
dox and immune adjuvants is more effective than the 
corresponding free therapy at inducing long-term 
tumor control and even complete remission in mice 
with MC-38 or TC-1 tumors and does not provoke any 
detectable side effects. 
 
 
Figure 3. Intratumoral co-delivery of dox with immune adjuvants boosts lymphocyte influx in the tumor microenvironment. At day 8, mice with TC-1 tumors 
received a single intratumoral injection of either PBS (mock control) or NP(dox+pIC+R848+MIP3α). Ten days later, the tumors were resected and analyzed by flow cytometry: 
(A) Representative flow cytometry plot showing CD45.2 cells in a mock (PBS) or treated tumor. The box and whiskers plot depicts n = 4 from one representative out of two 
independent experiments (p=0.0286). (B) Representative flow cytometry plot showing CD3+ cells in a mock (PBS) or treated tumor. The box and whiskers plot depicts n = 4 
from one representative out of two independent experiments (p=0.0286). (C) Representative flow cytometry plot showing CD4+ T cells in a mock (PBS) or treated tumor. The 
box and whiskers plot depicts n = 4 from one representative out of two independent experiments (p=0.0286). (D) Representative flow cytometry plot showing CD8+ T cells in 
a mock (PBS) or treated tumor. The box and whiskers plot depicts n = 4 from one representative out of two independent experiments (p=0.1143; n.s.). (E) Different cell types 
within the myeloid population analyzed in the tumor is depicted upon mock treated (PBS) tumors or treated tumors. n = 4 from one representative out of two independent 
experiments. (F) Different cell types within the myeloid population analyzed in the spleen is depicted upon mock treated (PBS) tumors or treated tumors. n = 4 from one 
representative out of two independent experiments. Statistics were calculated using a two-tailed Mann Whitney test. Statistical differences were considered significant at p < 0.05. 
* = p < 0.05; ** p = < 0.01; *** p < 0.001. Data plotted are presented as min to max. 
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Figure 4. Intratumoral co-delivery of dox and immune adjuvants by NPs augments the levels of circulating CD3+, CD8+ and cancer antigen-specific CD8+ 
T cells. Quantification of CD3+, CD8+ and the HPV16 E7 tetramer specific T cells in blood at day 16 and at day 26 (8 and 16 days post-treatment) after treatment with 
intratumoral NP(dox+pIC+R848+MIP3α) as compared with free dox or PBS (mock control). (A&B) The levels of CD3+ and CD8+ T cells collected from blood of mice at day 
16 (8 days after treatment) are depicted. n = 8 for NP(dox+pIC+R848+MIP3α), n = 8 for Dox and n = 5 for PBS. One representative out of two independent experiments. The 
differences between the groups are not statistically significant. (C) The levels of TM+ (cancer cell specific) CD3+CD8+ T cells collected from blood of mice at day 16 (8 days after 
treatment). n = 8 for NP(dox+pIC+R848+MIP3α), n = 8 for Dox and n = 5 for PBS. One representative out of two independent experiments. NP vs. dox (p=0.0351) and NP vs. 
PBS (p=0.0163). (D&E) The levels of CD3+ and CD8+ T cells collected from blood of mice at day 26 (18 days after treatment) are depicted. n = 8 for 
NP(dox+pIC+R848+MIP3α), n = 6 for Dox and n = 2 for PBS. One representative out of two independent experiments. The differences between the groups are not statistically 
significant. (F) The levels of TM+ (cancer cell specific) CD3+CD8+ T cells collected from blood of mice at day 26 (18 days after treatment). n = 8 for NP(dox+pIC+R848+MIP3α), 
n = 6 for Dox and n = 2 for PBS. One representative out of two independent experiments. The differences between the groups are not statistically significant. Statistics were 
calculated using a two-tailed Mann Whitney test. Statistical differences were considered significant at p < 0.05. * = p < 0.05; ** p = < 0.01; *** p < 0.001. All data are presented 
as mean ± SD. Abbreviations: TM: tetramer. 
 
Discussion 
Here, we report that the NP mediated delivery of 
dox and immune adjuvants induces complete 
remissions and effective long-term tumor control in 
both lung and colon mice tumor models. We show 
that the combinatorial treatment of chemotherapy 
with non-specific immunotherapy induces superior 
therapeutic responses which are attained when 
biomaterial nanotechnology is employed for the 
co-delivery. Furthermore, we show that the NP 
mediated chemoimmunotherapy modality augments 
the levels of lymphocytes and of cancer specific CD8+ 
T cells in the tumor and circulating in blood, leading 
to tumor eradications. 
For this paper, we prepared PEGylated PLGA 
NPs with an average size of approximately 180 nm, 
which is within the optimal functional range (40 nm to 
300 nm) reported for drug-delivery NPs [32–34]. 
When the NPs containing dox were co-cultured with 
cancer cells, more cancer cells were killed by dox 
inside NPs than an equal concentration of free dox. 
This finding could relate to a well-known drug efflux 
mechanism whereby transporters pump dox out of 
the cell [35]. Indeed, NP-delivered drugs have been 
reported to bypass efflux transporters, which also 
corroborates our results [36]. Nonetheless, the TC-1 
cells were more resistant to dox treatment than the 
MC-38 cells, independently of the delivery method. 
We also analyzed the established tumors after 
treatment and within the cell marker panels tested, we 
did not find any significant changes within the 
myeloid populations. This could be due to tumor cells 
overcoming acute inflammatory cytokines triggered 
by the TLR agonists. However, we did observe 
significant increases in the numbers of lymphocytes in 
the tumor, but not in the spleen. Furthermore, we 
analyzed the blood of treated mice at two different 
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time points and found that the combination therapy 
and the free dox monotherapy did not induce any 
reduction in the number of circulating lymphocytes. 
Together, these data indicate that, at the administered 
dose, the NP-delivered combination therapy did not 
reduce but rather increased the levels of lymphocytes 
in the tumor and did not affect the myeloid 
population within the parameters analyzed. 
However, at day 16 we found that only the 
combination treatment induced detectable numbers of 
cancer antigen-specific T cells. Similarly to 
radiotherapy or photo dynamic therapy, this 
evidences that cancer antigen-specific T cells can be 
generated without vaccination [37]. Furthermore, we 
report that co-delivery of dox and the immune 
adjuvants in a single NP provided significantly longer 
progression-free survival and overall survival in 
treated mice bearing MC-38 or TC-1 tumors compared 
to untreated mice. 
 
 
Figure 5. Intratumoral co-delivery of dox and immune adjuvants by NPs provides enhanced chemoimmunotherapeutic effects in mice with established 
tumors. (A) Schematic diagram of the TC-1 murine model experiment (C57BL/6 mice; n=8 per group, on average), showing inoculation and treatment days. (B) Tumor growth 
data from day 0 to day 80 for the PBS (control) group and four treatment groups (empty NPs, NP-delivered dox monotherapy, NP-delivered immune adjuvants and NP-delivered 
combination therapy). (C) Kaplan-Meier survival plots of pooled data, depicting progression-free survival and percent overall survival: NP(dox) vs. PBS p=0.0004; 
NP(pIC+R848+MIP3α) vs. PBS p=0.001; NP(dox+pIC+R848+MIP3α) vs. PBS p<0.0001; NP(dox+pIC+R848+MIP3α) vs. NP(pIC+R848+MIP3α) p=0.0082; 
NP(dox+pIC+R848+MIP3α) vs. NP(dox) p=0.0024; NP(empty) vs. PBS p=0.1082; NP(empty) vs. NP(dox) p=0.1160; NP(empty) vs. NP(pIC+R848+MIP3α) p=0.1076; NP(empty) 
vs. NP(dox+pIC+R848+MIP3α) p=0.0023. Survival curves were compared using the Gehan-Breslow-Wilcoxon test. Statistical differences were considered significant at * p = < 
0.05; ** p = < 0.01; *** p < 0.001. 
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Figure 6. Intratumoral co-delivery of dox and immune adjuvants by NPs induces strong tumor regression and better overall survival than does of free 
components. (A) Schematic diagram of the TC-1 and MC-38 murine (C57BL/6 mice) model experiments, showing inoculation and treatment days. (B) Tumor-growth data 
from day 0 to day 60 for the PBS (control) group and three treatment groups (free dox, free combination therapy and NP-delivered combination therapy) in the TC-1 (top) and 
MC-38 (bottom) models. (C) Kaplan-Meier survival plots depicting progression-free survival and percent overall survival for the TC-1 model upon indicated treatments. n = 8 
for each treatment group and n = 5 for PBS. NP(dox+pIC+R848+MIP3α) vs. PBS p=0.0041; Dox+pIC+R848+MIP3α vs. PBS p=0.0083; Dox vs. PBS p=0.0115; 
NP(dox+pIC+R848+MIP3α) vs. dox p=0.0113; NP(dox+pIC+R848+MIP3α) vs. Dox+pIC+R848+MIP3α p=0.0106. (D) Kaplan-Meier survival plots depicting progression-free 
survival and percent overall survival for the MC-38 model upon indicated treatments. n = 8 for NP(dox+pIC+R848+MIP3α), n=7 for Dox+pIC+R848+MIP3α, n=8 for Dox and 
n = 6 for PBS. NP(dox+pIC+R848+MIP3α) vs. PBS p=0.0008; Dox+pIC+R848+MIP3α vs. PBS p=0.0004; Dox vs. PBS p=0.1096; NP(dox+pIC+R848+MIP3α) vs. dox p=0.0004; 
NP(dox+pIC+R848+MIP3α) vs. Dox+pIC+R848+MIP3α p=0.0002. (E) The weight change of mice with TC-1 tumors after treatments. Data are presented as mean ± SD. (F) 
The weight change of mice with MC-38 tumors after treatments. Data are presented as mean ± SD. At day 25: NP(dox+pIC+R848+MIP3α) vs. dox p= 0.0121; 
Dox+pIC+R848+MIP3α vs. dox p= 0.0121. Survival curves were compared using the Gehan-Breslow-Wilcoxon test. Mice weight were analyzed by two-tailed Mann Whitney 
test. Statistical differences were considered significant at * p = < 0.05; ** p = < 0.01; *** p < 0.001. 
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Figure 7. Rational design of the nanoparticle-delivered chemoimmunotherapy to the tumor and tumor-draining lymph node. (Step 1) The NPs are injected 
in the tumors, whereby a part of the NPs are endocytosed by cancer and cancer associated cells. The NPs that were not endocytosed start to release their content in the 
extracellular space of which a portion also drains to the tumor-draining lymph node (and further). Due to the good NP stability, the drug release and their biological effects is 
sustained for a prolonged period of time. (Step 2) The cytostatic doxorubicin induces (cancer) cell death and the release of cancer antigens. (Step 3) The immune modulators 
pIC and R848 activate residing immature and suppressed immune cells in the tumor and tumor-draining lymph node. (Step 4) MIP3α recruits more immune cells into the tumor. 
 
Our NP-delivered combination therapy provides 
a triple mechanism based on the activity of dox, the 
chemokine MIP3α, and the TLR agonists pIC and 
R848 (Figure 7). Dox can induce the release of cancer 
antigens during cancer cell killing, but this effect 
alone often cannot provoke a sufficiently powerful 
immunological response for tumor clearance [38]. The 
chemokine MIP3α, can amplify the intratumoral 
immune response by recruiting T cells to the tumor. 
Furthermore, given that our NP concomitantly 
delivers specific TLRs, their activity likely abrogates 
the immunosuppressive signals that tumor cells send 
to immature DCs that process tumor antigens. 
Specifically, as some of the TLR agonists that partially 
leak into blood stimulate dividing T cells, those 
remaining inside the tumor cells maintain a favorable 
T cell environment. Finally, while the PLGA NPs 
themselves are non-cytotoxic and biocompatible, the 
direct activation of the inflammasome by PLGA in 
DCs has been reported [39,40]. 
Our findings are consistent with those of other 
groups, who have reported the benefits of NPs for 
delivery of chemotherapy and non-specific innate 
immunotherapy [41–44]. For instance, Roy et al. and 
Heo et al. treated murine B16 melanoma tumors with 
PLGA NPs containing paclitaxel and either a TLR4 or 
a TLR9 agonist, respectively [41,43]. The authors 
observed an initial delay in tumor growth and a 
significant influx of lymphocytes into the tumors. 
Moreover, Yin et al. treated B16 tumors with PLGA 
NPs containing dox and interferon γ [44]. The authors 
reported a delay in tumor growth, an influx of 
lymphocytes and NK cells into the tumors, and, in the 
tumor microenvironment, reduced levels of the 
suppressive cytokines IL-10 and TGFβ, and increased 
levels of IL-2 and TNFα. 
Despite the promising results for NP-delivered 
combination therapies in animal models of cancer, the 
translation to clinical use must be judiciously guided. 
In the few clinical trials in which patients with solid 
tumors were treated TLR agonist monotherapies, the 
treatment caused some cancers to regress but caused 
others to proliferate and metastasize [45]. For 
example, the strategy of activating TLR3 in lung 
cancer tumors appears to generate contradictory 
effects, inducing regressions in some tumors while 
conferring resistance in others [45,46]. In contrast, 
colon cancer cells exposed to TLR3 agonists have been 
reported to initiate apoptosis more rapidly [45]. The 
usage of slow-release vehicles, such as those enabled 
by nanotechnology, has been advocated for clinical 
therapy, since humans, unlike mice, are highly 
susceptible to cytokine release syndrome, a common 
side-effect of experimental immunotherapies [47–49]. 
Taken together, our results underscore the 
potential of NP-delivered chemoimmunotherapy to 
induce powerful anti-cancer immunity in solid, 
refractory tumors. We surmise that patients who are 
ineligible for surgery, or non-responsive to 
chemotherapy or immunotherapy, may benefit from 
this non-specific chemoimmunotherapy modality in 
the future. 
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